By 340B Matters Despite Big Pharma’s efforts to eviscerate the 340B Drug Discount Program, recent federal court decisions have made it clear that manufacturers are acting illegally. Eli Lilly, along with eight other huge drug makers, have unilaterally limited required drug discounts to safety-net health care...
By 340B Matters The drug industry already has some of the highest profit margins of any sector and they're getting higher for Eli Lilly. U.S. revenues increased by a whopping 26% last quarter - that’s a big jump for a company that posted $6 billion in...
By 340B Matters If there were any doubts about just how idiotic Big Pharma’s arguments can be against the 340B Drug Discount Program, look no further than Arkansas where the industry is desperate to stop a new law protecting it. This spring, Arkansas Governor Asa Hutchinson signed...
By 340B Matters The Department of Health and Human Services has referred six recalcitrant drug companies to the agency Inspector General for civil monetary penalties for denying 340B discounts to healthcare safety-net providers. There’s no question these six drug companies are guilty, guilty, guilty. We applaud the Health...
By 340B Matters Dear Secretary Becerra, On August 1 and September 1, Boehringer Ingelheim and Merck respectively began denying 340B discount pricing to safety-net healthcare providers that use contract pharmacies. This is in direct contravention of federal law. It’s part of an ongoing assault by the pharmaceutical...
By 340B Matters At long last, four top pharmaceutical companies are being sued under federal antitrust law for conspiring to deprive safety-net healthcare providers of lower pricing under the 340B Drug Discount Program. The suit, brought by Mosaic Health, a system of federally qualified health centers, charges...
By 340B Matters The 340B Drug Discount Program is getting robbed daily by insurers and pharmacy benefit managers. Finally, someone in Washington is doing something about it. A new bill in Congress called the Protect 340B Act would prohibit the pilfering and return the program to...
By 340B Matters German drug giant Boehringer Ingelheim has unwisely joined an ignominious group of manufacturers attacking the 340B Drug Discount Program. The result will be even less resources for America’s overburdened healthcare safety net. In late June, Boehringer informed 340B providers that it will stop offering...
By 340B Matters In the complex drug-pricing marketplace lies a murky underworld of pharmacy benefit managers (PBMs). Ostensibly, these companies negotiate lower drug pricing for insurers and (ideally) patients. They’re also now firmly rooted in the 340B Drug Discount Program reimbursement process and take a cut...
By 340B Matters In July 2020, six huge drug companies fired the first salvo in a war against a federal program that helps safety-net healthcare providers care for the underserved. Their outrageous attack on the 340B Drug Discount Program has left hospitals and clinics without vital...
